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OBJECTIVES: Racial disparities in diabetics exist in diabetes
control, as well as complications associated with diabetes. Such
disparities could lead to difference in likelihood of hospitaliza-
tion among different races. This study examined the association
between patients’ race and hospitalization in type 2 diabetes
patients newly starting oral antidiabetic therapy. METHODS:
This was a retrospective cohort study of Medicaid insured
patients with type-2 diabetes newly starting oral antidiabetic
medication (metformin, sulfonylureas, thiazolidinediones). A
cohort of type 2 diabetes patients was identiﬁed using ICD-9
code (250.xx) and 1 National Drug Code for antidiabetic med-
ication. Information for demographic factors (race, age of
patient, gender of the patient), clinical factors (severity of dia-
betes, number of comorbidities), medication related factors
(number of medications consumed), and access to care (number
of diabetes related physician visits) was extracted from the data-
base. Patients’ race was categorized as African Americans,
Whites and Others. Hospitalization was measured as a categor-
ical dichotomous variable. Patients were followed up for one
year after the index date of new medication. Multiple logistic
regression for three cohorts was performed to assess the associ-
ation patients’ race and likelihood of hospitalization adjusting
for above mentioned factors. RESULTS: Among metformin users
(n = 215), there was no difference in the likelihood of hospital-
ization between races. Among sulfonylureas users (n = 1171),
there was no difference in the likelihood of hospitalization
between races. Among thiazolidinedione users (n = 1751),
African Americans were associated with 39% increased likeli-
hood of hospitalization as compared to whites (OR: 1.39, 95%
CI: 1.07–1.81). Number of medications and comorbidities were
found to be signiﬁcant predictors in each of the analyses. CON-
CLUSION: Racial differences in hospitalizations among thiazo-
lidinediones users should be investigated to understand other
factors that contribute to hospitalization in this group. Avoiding
hospitalization among these patients would generate consider-
able cost savings.
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OBJECTIVES: To determine: 1) the utilization and expenditures
of pioglitazone after the decision of drug reimbursement, and 2)
the addition (adding of pioglitazone to the treatment) or substi-
tution (switching from other anti-diabetic agents to pioglitazone)
effect of pioglitazone introduction. METHODS: Retrospective
database analysis was carried out from the payer’s (BNHI) per-
spective. Overall treatment resource from 5-year BNHI claimed-
database of diabetic patients (ICD-9-CM: 250.XX), including
OPD and hospitalized data from January 2000 to December
2004, were extracted. However, only pharmaceutical expendi-
tures of anti-diabetic agents were analyzed. Drug prices were
BNHI reimbursed prices, and discount rate was not considered.
RESULTS: Five-year database contains population of 0.92, 0.98,
1.02, 1.05 and 1.14 million people from 2000 to 2004 respec-
tively in Taiwan with diabetes (including type 1 and type 2 DM).
In 2002, the expenditure of pioglitazone reimbursed by BNHI
was NT$ 37.2 million (1.02% of total anti-diabetic agents), and
it increased signiﬁcantly in 2003 (NT$ 231.2 million) and 2004
(NT$ 359.4 million) but approached saturation at last few
months of 2004. It was assumed that if the anti-diabetic agents
were not substituted by pioglitazone, patients would still be
using them for one year. The effect of drug substitution in 2002,
2003 and 2004 were NT$ 14.4 million, 61.4 million and 41.4
million, respectively. The order of substitution by expenditure of
pioglitazone was rosiglitazone, acarbose and metformin. Sub-
tracting the substituted expenditure, the reimbursement of
pioglitazone only burdened insurer NT$ 22.8 million, NT$
169.7 million and NT$ 318.0 million in 2002, 2003 and 2004,
respectively. The cost effect of adverse drug reactions is difﬁcult
to evaluate in the retrospective data analysis. CONCLUSION:
The ﬁnancial burden of introducing the new drug to a health
insurance program should not consider only the expenditure of
the new drug itself. The substitution effect should be deducted
in the budget impact analysis.
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OBJECTIVES: To conduct a cost-beneﬁt analysis (CBA) for
inhaled drug delivery system for insulin (INI). METHODS: Pre-
viously, we reported the average monthly willingness-to-pay
(WTP) for INI from diabetic patient (Cdn$153.70 ± $99.90) 
and general population (Cdn$68.59 ± $44.65) perspective in
Canada. This study estimates the net beneﬁt and cost-beneﬁt
ratio for INH from both patient and general population per-
spective. The average cost of insulin therapy using subcutaneous
insulin injection (SCI) was calculated equal to Cdn$32.40 per
month based on average 40 units daily usage of rapid acting
insulin for bolus insulin supplement. The cost of self-injection
was approximately Cdn$8.40. One form of INI is available using
powder form of insulin and a liquid inhaler is under develop-
ment. The average daily cost of inhaled delivery system for
insulin is approximately 40% higher than SCI. Using the same
price premium ratio we estimated the average monthly cost of
INI in Canada equal to Cdn$45.36 (when being available). The
cost of basal insulin and self blood-glucose monitoring was con-
sidered equal. RESULTS: In the base-case scenario, the net
beneﬁt of INI when compared to SCI was Cdn$90.74 per month
from the diabetic patient perspective and Cdn$5.63 from the
general population perspective. The cost-beneﬁt ratio (CBR—
calculated as ÄCost/ÄWTP) from the patient (0.12) and the
general population (0.69) perspective were <1, suggestive of a
positive CBR for INI. Extensive sensitivity analysis was per-
formed by changing variables (set apriori) including INI price
(+10%, 20%) and daily usage of insulin units (±10%, 20%).
Results of the analysis were robust to the changes in variables.
CONCLUSION: This analysis demonstrated that the beneﬁts of
inhaled delivery system for insulin for control of blood glucose
levels in diabetic patients are greater than the costs, therefore
The rapy provide a positive net beneﬁt from both patient and
general population perspective and is a good investment for
money.
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OBJECTIVES: This study examined resource utilization and
direct, indirect, and procedure-related costs associated with pho-
tocoagulation and vitrectomy procedures among employees with
diabetic retinopathy (DR). METHODS: Health care utilization
and costs of DR employees age 18–64 were examined using
claims from 17 large self-insured U.S. employers (1999–2004).
Indirect costs (work loss, absenteeism) were estimated using dis-
ability claims and absenteeism information. The study sample
included employees who had at least one diagnosis of DR based
on ICD-9 codes and were enrolled continuously for 12 months.
Cost outcomes were examined over a randomly chosen 12-
month (study) period following the DR diagnosis. Annual total
(i.e., health care plus indirect) costs (2005 USD) were compared
between DR employees who did and did not undergo a proce-
dure. Utilization and costs were measured on the procedure date
and during the 30-day follow-up period. RESULTS: The study
sample consisted of 2,098 DR employees. The average age was
51 years; 67.4% were male and 64.7% had type I diabetes.
Approximately 11.8% (n = 247) of DR employees received pho-
tocoagulation procedures during the study period; 2.1% (n = 44)
received vitrectomies. DR employees with photocoagulations
had average total costs that were approximately double those of
other DR employees ($34,539 vs. $16,041, p < 0.001); employ-
ees with vitrectomies had costs that were over 3.5 times higher
than non-vitrectomy DR employees ($63,933 vs. $17,239, p <
0.001). Indirect costs accounted for about 10% of these differ-
ences. More than half (58.7%) of employees had multiple pho-
tocoagulations within the study period and the majority of
employees with vitrectomies received multiple procedures on the
same day. Most (76%) photocoagulations were performed in
physicians’ ofﬁces; nearly all (96%) vitrectomies were performed
in an outpatient or ambulatory surgery setting. CONCLUSION:
Photocoagulation and vitrectomy procedures were associated
with substantially higher costs among DR employees. Indirect
costs were a substantial but not dominant driver of cost 
differences.
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OBJECTIVES: Diabetes mellitus type 2 (DM2) is a high preva-
lence disease in Mexico which represented expenditures in the
Mexican Health System above US$450 millions. The purpose of
this study was to compare the cost–effectiveness ratios between
multiple pharmacologic treatments for adult patients with DM2
who didn’t reach metabolic control (HbAC1 < 7%) using oral
hypoglycemic agents or diet from the Mexican health care
payer’s perspective. METHODS: We used a ten-year Markov
analysis model to estimate costs and effectiveness. Markov
model includes several DM2 complications stages (retinopathy,
cardiovascular diseases, neuropathy, nephropathy and death).
Effectiveness measure was the number of life years gained (LYG).
Transition probabilities were obtained from international pub-
lished literature (UKPDS studies). Comparators were: NPH
insulin, glargine insulin, inhalable insulin, NPH insulin + met-
formin and pioglitazone + metformin. Resource use estimations
were performed employing hospital records in second and third
health care level hospitals from the Social Security Mexican Insti-
tute in Mexico City (n = 311). Costs included emergency, out-
patient and inpatient services, drugs, comorbidities procedures,
etc. Costs and LYG were discounted 5% annually. One-way and
probabilistic sensitivity analyses were performed and acceptabil-
ity curves were constructed. RESULTS: Expected costs for
patients using inhalable insulin resulted in US$17,997, followed
by NPH insulin (US$19,433), glargine insulin (US$20,338),
NPH insulin + metformin (US$19,642) and pioglitazone + met-
formin (US$25,258). LYG per patient resulted in 8.13 yrs with
inhalable insulin vs. 8.05 yrs with the other therapies in average.
ICERs for inhalable insulin against other therapies resulted
within the range US$2213–US$3141. Results were robust to
Monte Carlo ﬁrst order sensitivity analysis and acceptability
curves showed that inhalable insulin was the option most cost-
effective with a 69.9% of certainty. CONCLUSION: Despite its
higher cost in the Mexican market, inhalable insulin was in the
long term the most cost—effective option for the treatment of
DM2 patients who didn’t reach metabolic control.
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OBJECTIVES: To determine the cost-effectiveness of V.A.C.
Therapy compared to advanced wound dressings (Dermagraft
and Apligraf), for diabetic foot ulcer patients treated in the U.S.
METHODS: A Markov model was designed to estimate the cost
per amputation avoided and the cost per quality-adjusted life
year (QALY) of V.A.C. Therapy compared to advanced dress-
ings. Over a one-year period, the Markov model simulated 1000
patients using transition probabilities obtained from the litera-
ture. The health states used in the model were uninfected ulcer,
infected ulcer, infected ulcer post-amputation, healed, healed
post-amputation, amputation, and death. Unhealed V.A.C.
treated patients were switched to the advanced dressing after
three months of treatment while unhealed advanced dressing
treated patients continued on their advanced dressing for any
remaining months. RESULTS: The model results demonstrate
that V.A.C. Therapy dominates the advanced dressing compara-
tor. Over one-year, V.A.C. will result in more QALYs gained
(0.54 versus 0.53 per person), less amputations (0.0011 versus
0.0012, per person) and a higher percentage of healed wounds
(61% vs. 59%) and 0.68 more ulcer free months (5.79 vs. 5.11)
at an overall lower cost of care ($52,830 vs. $61,757; per
person). CONCLUSION: The model results indicate that V.A.C.
Therapy is less costly and more effective than the advanced dress-
ing comparator. The results are robust to changes of key para-
meters, including the comparator (traditional versus advanced),
transition probabilities, cost of V.A.C., and the utility weights.
Extending the model for a longer period (three years) resulted in
even greater cost savings in the V.A.C. arm (e.g., the incremen-
tal cost would be −$10,101 and the incremental QALY would
be 0.009, per person, using a 3.5% discount rate for costs and
beneﬁts).
